The Neuroscience of Dementia brings together different fields of dementia research into a single book, covering a wide range of subjects, including Alzheimer’s disease, Lewy body dementia, mixed dementia, vascular dementia, physical activity, risk factors, mortality, biomarkers, SPECT, CT, MRI, questionnaires, nutrition, sleep, delirium, hearing loss, agitation, aggression, delusions, anxiety, depression, hallucinations, psychosis, senile plaques, tau and amyloid-beta, neuroinflammation, molecular biology, and more. This foundational, comprehensive book compiles the latest understanding on all forms of dementia and their common features in a single source. It is an invaluable resource for neuroscientists, neurologists, and anyone in the field.
1. Cover image - p. i 2. Title page - p. ii 3. Table of Contents - p. iii 4. Copyright - p. iv 5. Dedication - p. v 6. Contributors of Volume 1 - p. v 7. Contributors of Volume 2 - p. xiii 8. Foreword - p. xxiii 9. Preface of Volume 1 - p. xxv 10. Preface of Volume 2 - p. xxvii 11. Volume 1 - p. xxviii 12. Part I. Dementia: introductory chapters and setting the scene - p. xxviii 13. Chapter 1. Mixed dementia: a neuropathological overview - p. xxviii 14. Chapter 2. Vascular dementia: an overview - p. xxviii 15. Chapter 3. Small vessel disease and dementia - p. xxviii 16. Chapter 4. Linking amyotrophic lateral sclerosis and frontotemporal dementia - p. 40 17. Chapter 5. Mortality in dementia: linking in the role of delirium - p. 56 18. Chapter 6. Midlife diabetes and the risk of dementia: understanding the link - p. 56 19. Chapter 7. Gait and dementia - p. 56 20. Chapter 8. The role of blood pressure and hypertension in dementia - p. 56 21. Chapter 9. Genetics of dementia: a focus on Alzheimer's disease - p. 114 22. Chapter 10. Clinical and pathological phenotypes in dementia: a focus on autosomal dominant frontotemporal dementia - p. 146 23. Chapter 11. Environmental and genetic risk factors for dementia - p. 162 24. Chapter 12. Lipids, brain ageing, dementia, and lipidomics - p. 162 25. Chapter 13. The 5×FAD mouse model of Alzheimer's disease - p. 194 26. Part II. Biomarkers, psychometric instruments and diagnosis - p. 194 27. Chapter 14. Use of cerebrospinal fluid in diagnosis of dementia - p. 194 28. Chapter 15. Salivary biomarkers in Alzheimer's disease - p. 194 29. Chapter 16. Diacylglycerols: biomarkers of a sustained immune response in proteinopathies - p. 194 30. Chapter 17. Butyrylcholinesterase as a biomarker in Alzheimer’s disease - p. 260 31. Chapter 18. Blood brain-derived neurotrophic factor as a biomarker of Alzheimer's disease - p. 260 32. Chapter 19. The neuroscience of dementia: diagnosis and management methods of amyloid positron emission tomography imaging and its application to the Alzheimer's disease spectrum - p. 260 33. Chapter 20. Diffusion-weighted imaging (DWI) tractography and Alzheimer's disease - p. 308 34. Chapter 21. Transcranial magnetic stimulation in the cortical exploration of dementia - p. 308 35. Chapter 22. The role of retinal imaging in Alzheimer's disease - p. 342 36. Chapter 23. Prediction of Alzheimer's disease - p. 356 37. Chapter 24. Addenbrooke's Cognitive Examination - p. 372 38. Chapter 25. Beyond the cutoffs: a Bayesian approach to the use of the Montreal Cognitive Assessment as a screening tool for mild cognitive impairment and dementia - p. 388 39. Chapter 26. Utility of ALBA screening instrument: the prodromal phase of dementia with Lewy bodies - p. 406 40. Chapter 27. The quick mild cognitive impairment screen and applications to dementia - p. 406 41. Chapter 28. The usefulness of evaluating performance of activities of daily living in the diagnosis of mild cognitive disorders - p. 440 42. Part III. Pharmacological treatments for dementia - p. 440 43. Chapter 29. Cholinesterase inhibitors in dementias: an overview - p. 440 44. Chapter 30. Choline-containing phospholipids and treatment of adult-onset dementia disorders - p. 472 45. Chapter 31. Donepezil in the treatment of Alzheimer's disease - p. 472 46. Chapter 32. Memantine and Alzheimer's disease: a comprehensive review - p. 472 47. Chapter 33. A new neuroprotective strategy for the drug therapy of Parkinson's disease: the Ca2+/cAMP signaling as therapeutic target - p. 520 48. Chapter 34. Pitfalls and possible solutions for research and development of dementia therapies - p. 520 49. Chapter 35. All-trans retinoic acid in Alzheimer's disease - p. 554 50. Chapter 36. Dementia and usage of N-methyl-d-aspartate receptor antagonists - p. 568 51. Chapter 37. Swallowing impairment in Parkinson's disease - p. 582 52. Chapter 38. Linking astrocytes' exosomes to Alzheimer pathogenesis and therapy - p. 582 53. Chapter 39. Changing fate: therapeutic mechanisms focused on the switch of amyloid precursor protein processing - p. 582 54. Chapter 40. Acetylcholinesterase inhibitory agents in plants and their application to dementia: Alzheimer's disease - p. 582 55. Chapter 41. Removal of blood amyloid-β as an effective and safe therapeutic strategy for Alzheimer's disease - p. 582 56. Part IV. Non-pharmacological treatments and procedures - p. 582 57. Chapter 42. Caring for people with dementia in the acute hospital - p. 582 58. Chapter 43. Environmental enrichment as a preventative and therapeutic approach to Alzheimer's disease - p. 582 59. Chapter 44. Music therapy in dementia: The effects of music therapy and other musical interventions on behavior, emotion, and cognition - p. 582 60. Chapter 45. Exploitation of aromatherapy in dementia—impact on pain and neuropsychiatric symptoms - p. 582 61. Chapter 46. Dancing in dementia - p. 724 62. Chapter 47. Hypoxic–hyperoxic conditioning and dementia - p. 724 63. Chapter 48. Linking amyloid and depression in the development of Alzheimer's disease: Effects of neuromodulatory interventions by brain stimulation - p. 724 64. Chapter 49. Regional and local dementia care networks - p. 768 65. Chapter 50. Cognitive behavioral therapy use in Alzheimer's disease: Mitigating risks associated with the olfactory brain - p. 782 66. Chapter 51. Maximizing cognition in mild cognitive impairment and early stage dementia - p. 782 67. Chapter 52. Exercise, cognitive creativity, and dementia - p. 812 68. Chapter 53. Person-centered communication among formal caregivers of persons with dementia - p. 832 69. Volume 2 - p. 848 70. Part I. Genetics, molecular and cellular biology - p. 848 71. Chapter 1. The neuron navigator 2 gene and Alzheimer's disease - p. 3 72. Chapter 2. Interlinking polymorphisms, estrogens, and Alzheimer disease - p. 25 73. Chapter 3. Linking EEGs, Alzheimer disease, and the phosphatidylinositol-binding clathrin assembly protein (PICALM) gene - p. 41 74. Chapter 4. CD36 gene polymorphisms and Alzheimer's disease - p. 57 75. Chapter 5. Genetic contributions to sporadic frontotemporal dementia - p. 71 76. Chapter 6. Clinical response to cholinesterase inhibitors in dementia: the role of CYP2D6 and APOE genetic polymorphisms - p. 89 77. Chapter 7. A1 and A2 purinergic receptor expression in dementia - p. 103 78. Chapter 8. Molecular aspects of metallothioneins in dementias - p. 115 79. Chapter 9. Implication of microRNAs in Alzheimer's disease pathogenesis - p. 131 80. Chapter 10. Role of cellular oxidative stress in dementia - p. 147 81. Chapter 11. Toward an integrative understanding of the neuroinflammatory molecular milieu in Alzheimer disease neurodegeneration - p. 163 82. Chapter 12. Wnt signaling and dementia - p. 177 83. Chapter 13. Linkage of atypical protein kinase C to Alzheimer disease - p. 195 84. Chapter 14. Linking histone deacetylases and phosphodiesterase 5 in novel treatments for Alzheimer's disease - p. 213 85. Chapter 15. Nuclear factor erythroid 2-related factor 2 in Alzheimer's disease - p. 227 86. Chapter 16. Implications of alpha- and beta-secretase expression and function in Alzheimer's disease - p. 245 87. Chapter 17. Methylation analysis of DNA in Alzheimer's disease - p. 261 88. Chapter 18. The signalosome malfunctions in age-associated neuropathologies - p. 275 89. Chapter 19. FAM3C in Alzheimer's disease: a risk-related molecule and potential therapeutic target - p. 293 90. Chapter 20. Amylin and amylin receptors in Alzheimer's disease - p. 309 91. Chapter 21. Mammalian target of rapamycin complexes: regulation and Alzheimer's disease - p. 325 92. Chapter 22. Mammalian target of rapamycin complexes: protein synthesis and autophagy, Parkinson's disease, amyotrophic lateral sclerosis, and frontotemporal dementia - p. 343 93. Chapter 23. Linking CD200 in brains and dementia: molecular aspects of neuroinflammation - p. 357 94. Part II. Neurological, physiological and imaging - p. 369 95. Chapter 24. Hippocampal atrophy associated with dementia risk factors and dementia - p. 373 96. Chapter 25. Inflammation and insulin resistance in Alzheimer’s disease: partners in crime - p. 389 97. Chapter 26. Brain susceptibility to hypoxia/hypoxemia and metabolic dysfunction in Alzheimer's disease: insights from animal and in vitro models - p. 407 98. Chapter 27. Neuropeptides and neurolipids: what they are and how they relate to Alzheimer’s disease - p. 423 99. Chapter 28. Neurotransmitter receptors in Alzheimer's disease: from glutamatergic to cholinergic receptors - p. 441 100. Chapter 29. Aβ42-α7-like nicotinic acetylcholine receptors and Alzheimer’s disease - p. 457 101. Chapter 30. Synaptosomal bioenergetic defects in Alzheimer's disease - p. 473 102. Chapter 31. Limitations of amyloid imaging in Alzheimer's disease - p. 491 103. Chapter 32. Linking gradient echo plural contrast imaging metrics of tissue microstructure with Alzheimer disease - p. 507 104. Chapter 33. Hypertensive disorders during pregnancy and later dementia: is there a connection? - p. 521 105. Chapter 34. Unraveling the contributions of sleep dysfunction to Alzheimer's disease - p. 539 106. Part III. Behaviour and psychopathology - p. 552 107. Chapter 35. Overview of behaviors in dementia - p. 555 108. Chapter 36. Delirium superimposed on dementia: a clinical challenge from diagnosis to treatment - p. 569 109. Chapter 37. Self-consciousness deficits in dementia - p. 583 110. Chapter 38. Attentional impairments to novel images in dementia - p. 597 111. Chapter 39. Frontal lobe syndrome and dementias - p. 617 112. Chapter 40. The stigma of dementia - p. 633 113. Chapter 41. Delusions in dementias - p. 647 114. Chapter 42. Linking motor speech function and dementia - p. 665 115. Chapter 43. Spatial navigation and Alzheimer's disease - p. 677 116. Chapter 44. Violence and dementia - p. 693 117. Chapter 45. Factors contributing to protection and vulnerability in dementia caregivers - p. 709 118. Part IV. Diet, nutrition and environment - p. 722 119. Chapter 46. Nutritional status of dementia and management using dietary taurine supplementation - p. 725 120. Chapter 47. Selenium and Alzheimer's disease - p. 739 121. Chapter 48. Linking adiponectin and obesity in dementia - p. 749 122. Chapter 49. The impact of the gut microbiome in Alzheimer's disease: cause or consequence? - p. 769 123. Chapter 50. (-)-Epigallocatechin-3-gallate and Alzheimer's disease - p. 783 124. Chapter 51. Lead, cadmium and Alzheimer’s disease - p. 813 125. Part V. Models and modelling in dementia - p. 830 126. Chapter 52. Alzheimer model 5xfad mice and applications to dementia: transgenic mouse models, a focus on neuroinflammation, microglia, and food-derived components - p. 833 127. Chapter 53. Use of 192 IgG-saporin as a model of dementia and its application - p. 849 128. Chapter 54. Amyloid beta 1–42-induced animal model of dementia: a review - p. 856 129. Chapter 55. Resources for the neuroscience of dementia - p. 856 130. Index of Volume 1 - p. 857 131. Index of Volume 2 - p. 897
The Neuroscience of Dementia brings together different fields of dementia research into a single book, covering a wide range of subjects, including Alzheimer’s disease, Lewy body dementia, mixed dementia, vascular dementia, physical activity, risk factors, mortality, biomarkers, SPECT, CT, MRI, questionnaires, nutrition, sleep, delirium, hearing loss, agitation, aggression, delusions, anxiety, depression, hallucinations, psychosis, senile plaques, tau and amyloid-beta, neuroinflammation, molecular biology, and more. This foundational, comprehensive book compiles the latest understanding on all forms of dementia and their common features in a single source. It is an invaluable resource for neuroscientists, neurologists, and anyone in the field.
1. Cover image - p. i 2. Title page - p. ii 3. Table of Contents - p. iii 4. Copyright - p. iv 5. Dedication - p. v 6. Contributors of Volume 1 - p. v 7. Contributors of Volume 2 - p. xiii 8. Foreword - p. xxiii 9. Preface of Volume 1 - p. xxv 10. Preface of Volume 2 - p. xxvii 11. Volume 1 - p. xxviii 12. Part I. Dementia: introductory chapters and setting the scene - p. xxviii 13. Chapter 1. Mixed dementia: a neuropathological overview - p. xxviii 14. Chapter 2. Vascular dementia: an overview - p. xxviii 15. Chapter 3. Small vessel disease and dementia - p. xxviii 16. Chapter 4. Linking amyotrophic lateral sclerosis and frontotemporal dementia - p. 40 17. Chapter 5. Mortality in dementia: linking in the role of delirium - p. 56 18. Chapter 6. Midlife diabetes and the risk of dementia: understanding the link - p. 56 19. Chapter 7. Gait and dementia - p. 56 20. Chapter 8. The role of blood pressure and hypertension in dementia - p. 56 21. Chapter 9. Genetics of dementia: a focus on Alzheimer's disease - p. 114 22. Chapter 10. Clinical and pathological phenotypes in dementia: a focus on autosomal dominant frontotemporal dementia - p. 146 23. Chapter 11. Environmental and genetic risk factors for dementia - p. 162 24. Chapter 12. Lipids, brain ageing, dementia, and lipidomics - p. 162 25. Chapter 13. The 5×FAD mouse model of Alzheimer's disease - p. 194 26. Part II. Biomarkers, psychometric instruments and diagnosis - p. 194 27. Chapter 14. Use of cerebrospinal fluid in diagnosis of dementia - p. 194 28. Chapter 15. Salivary biomarkers in Alzheimer's disease - p. 194 29. Chapter 16. Diacylglycerols: biomarkers of a sustained immune response in proteinopathies - p. 194 30. Chapter 17. Butyrylcholinesterase as a biomarker in Alzheimer’s disease - p. 260 31. Chapter 18. Blood brain-derived neurotrophic factor as a biomarker of Alzheimer's disease - p. 260 32. Chapter 19. The neuroscience of dementia: diagnosis and management methods of amyloid positron emission tomography imaging and its application to the Alzheimer's disease spectrum - p. 260 33. Chapter 20. Diffusion-weighted imaging (DWI) tractography and Alzheimer's disease - p. 308 34. Chapter 21. Transcranial magnetic stimulation in the cortical exploration of dementia - p. 308 35. Chapter 22. The role of retinal imaging in Alzheimer's disease - p. 342 36. Chapter 23. Prediction of Alzheimer's disease - p. 356 37. Chapter 24. Addenbrooke's Cognitive Examination - p. 372 38. Chapter 25. Beyond the cutoffs: a Bayesian approach to the use of the Montreal Cognitive Assessment as a screening tool for mild cognitive impairment and dementia - p. 388 39. Chapter 26. Utility of ALBA screening instrument: the prodromal phase of dementia with Lewy bodies - p. 406 40. Chapter 27. The quick mild cognitive impairment screen and applications to dementia - p. 406 41. Chapter 28. The usefulness of evaluating performance of activities of daily living in the diagnosis of mild cognitive disorders - p. 440 42. Part III. Pharmacological treatments for dementia - p. 440 43. Chapter 29. Cholinesterase inhibitors in dementias: an overview - p. 440 44. Chapter 30. Choline-containing phospholipids and treatment of adult-onset dementia disorders - p. 472 45. Chapter 31. Donepezil in the treatment of Alzheimer's disease - p. 472 46. Chapter 32. Memantine and Alzheimer's disease: a comprehensive review - p. 472 47. Chapter 33. A new neuroprotective strategy for the drug therapy of Parkinson's disease: the Ca2+/cAMP signaling as therapeutic target - p. 520 48. Chapter 34. Pitfalls and possible solutions for research and development of dementia therapies - p. 520 49. Chapter 35. All-trans retinoic acid in Alzheimer's disease - p. 554 50. Chapter 36. Dementia and usage of N-methyl-d-aspartate receptor antagonists - p. 568 51. Chapter 37. Swallowing impairment in Parkinson's disease - p. 582 52. Chapter 38. Linking astrocytes' exosomes to Alzheimer pathogenesis and therapy - p. 582 53. Chapter 39. Changing fate: therapeutic mechanisms focused on the switch of amyloid precursor protein processing - p. 582 54. Chapter 40. Acetylcholinesterase inhibitory agents in plants and their application to dementia: Alzheimer's disease - p. 582 55. Chapter 41. Removal of blood amyloid-β as an effective and safe therapeutic strategy for Alzheimer's disease - p. 582 56. Part IV. Non-pharmacological treatments and procedures - p. 582 57. Chapter 42. Caring for people with dementia in the acute hospital - p. 582 58. Chapter 43. Environmental enrichment as a preventative and therapeutic approach to Alzheimer's disease - p. 582 59. Chapter 44. Music therapy in dementia: The effects of music therapy and other musical interventions on behavior, emotion, and cognition - p. 582 60. Chapter 45. Exploitation of aromatherapy in dementia—impact on pain and neuropsychiatric symptoms - p. 582 61. Chapter 46. Dancing in dementia - p. 724 62. Chapter 47. Hypoxic–hyperoxic conditioning and dementia - p. 724 63. Chapter 48. Linking amyloid and depression in the development of Alzheimer's disease: Effects of neuromodulatory interventions by brain stimulation - p. 724 64. Chapter 49. Regional and local dementia care networks - p. 768 65. Chapter 50. Cognitive behavioral therapy use in Alzheimer's disease: Mitigating risks associated with the olfactory brain - p. 782 66. Chapter 51. Maximizing cognition in mild cognitive impairment and early stage dementia - p. 782 67. Chapter 52. Exercise, cognitive creativity, and dementia - p. 812 68. Chapter 53. Person-centered communication among formal caregivers of persons with dementia - p. 832 69. Volume 2 - p. 848 70. Part I. Genetics, molecular and cellular biology - p. 848 71. Chapter 1. The neuron navigator 2 gene and Alzheimer's disease - p. 3 72. Chapter 2. Interlinking polymorphisms, estrogens, and Alzheimer disease - p. 25 73. Chapter 3. Linking EEGs, Alzheimer disease, and the phosphatidylinositol-binding clathrin assembly protein (PICALM) gene - p. 41 74. Chapter 4. CD36 gene polymorphisms and Alzheimer's disease - p. 57 75. Chapter 5. Genetic contributions to sporadic frontotemporal dementia - p. 71 76. Chapter 6. Clinical response to cholinesterase inhibitors in dementia: the role of CYP2D6 and APOE genetic polymorphisms - p. 89 77. Chapter 7. A1 and A2 purinergic receptor expression in dementia - p. 103 78. Chapter 8. Molecular aspects of metallothioneins in dementias - p. 115 79. Chapter 9. Implication of microRNAs in Alzheimer's disease pathogenesis - p. 131 80. Chapter 10. Role of cellular oxidative stress in dementia - p. 147 81. Chapter 11. Toward an integrative understanding of the neuroinflammatory molecular milieu in Alzheimer disease neurodegeneration - p. 163 82. Chapter 12. Wnt signaling and dementia - p. 177 83. Chapter 13. Linkage of atypical protein kinase C to Alzheimer disease - p. 195 84. Chapter 14. Linking histone deacetylases and phosphodiesterase 5 in novel treatments for Alzheimer's disease - p. 213 85. Chapter 15. Nuclear factor erythroid 2-related factor 2 in Alzheimer's disease - p. 227 86. Chapter 16. Implications of alpha- and beta-secretase expression and function in Alzheimer's disease - p. 245 87. Chapter 17. Methylation analysis of DNA in Alzheimer's disease - p. 261 88. Chapter 18. The signalosome malfunctions in age-associated neuropathologies - p. 275 89. Chapter 19. FAM3C in Alzheimer's disease: a risk-related molecule and potential therapeutic target - p. 293 90. Chapter 20. Amylin and amylin receptors in Alzheimer's disease - p. 309 91. Chapter 21. Mammalian target of rapamycin complexes: regulation and Alzheimer's disease - p. 325 92. Chapter 22. Mammalian target of rapamycin complexes: protein synthesis and autophagy, Parkinson's disease, amyotrophic lateral sclerosis, and frontotemporal dementia - p. 343 93. Chapter 23. Linking CD200 in brains and dementia: molecular aspects of neuroinflammation - p. 357 94. Part II. Neurological, physiological and imaging - p. 369 95. Chapter 24. Hippocampal atrophy associated with dementia risk factors and dementia - p. 373 96. Chapter 25. Inflammation and insulin resistance in Alzheimer’s disease: partners in crime - p. 389 97. Chapter 26. Brain susceptibility to hypoxia/hypoxemia and metabolic dysfunction in Alzheimer's disease: insights from animal and in vitro models - p. 407 98. Chapter 27. Neuropeptides and neurolipids: what they are and how they relate to Alzheimer’s disease - p. 423 99. Chapter 28. Neurotransmitter receptors in Alzheimer's disease: from glutamatergic to cholinergic receptors - p. 441 100. Chapter 29. Aβ42-α7-like nicotinic acetylcholine receptors and Alzheimer’s disease - p. 457 101. Chapter 30. Synaptosomal bioenergetic defects in Alzheimer's disease - p. 473 102. Chapter 31. Limitations of amyloid imaging in Alzheimer's disease - p. 491 103. Chapter 32. Linking gradient echo plural contrast imaging metrics of tissue microstructure with Alzheimer disease - p. 507 104. Chapter 33. Hypertensive disorders during pregnancy and later dementia: is there a connection? - p. 521 105. Chapter 34. Unraveling the contributions of sleep dysfunction to Alzheimer's disease - p. 539 106. Part III. Behaviour and psychopathology - p. 552 107. Chapter 35. Overview of behaviors in dementia - p. 555 108. Chapter 36. Delirium superimposed on dementia: a clinical challenge from diagnosis to treatment - p. 569 109. Chapter 37. Self-consciousness deficits in dementia - p. 583 110. Chapter 38. Attentional impairments to novel images in dementia - p. 597 111. Chapter 39. Frontal lobe syndrome and dementias - p. 617 112. Chapter 40. The stigma of dementia - p. 633 113. Chapter 41. Delusions in dementias - p. 647 114. Chapter 42. Linking motor speech function and dementia - p. 665 115. Chapter 43. Spatial navigation and Alzheimer's disease - p. 677 116. Chapter 44. Violence and dementia - p. 693 117. Chapter 45. Factors contributing to protection and vulnerability in dementia caregivers - p. 709 118. Part IV. Diet, nutrition and environment - p. 722 119. Chapter 46. Nutritional status of dementia and management using dietary taurine supplementation - p. 725 120. Chapter 47. Selenium and Alzheimer's disease - p. 739 121. Chapter 48. Linking adiponectin and obesity in dementia - p. 749 122. Chapter 49. The impact of the gut microbiome in Alzheimer's disease: cause or consequence? - p. 769 123. Chapter 50. (-)-Epigallocatechin-3-gallate and Alzheimer's disease - p. 783 124. Chapter 51. Lead, cadmium and Alzheimer’s disease - p. 813 125. Part V. Models and modelling in dementia - p. 830 126. Chapter 52. Alzheimer model 5xfad mice and applications to dementia: transgenic mouse models, a focus on neuroinflammation, microglia, and food-derived components - p. 833 127. Chapter 53. Use of 192 IgG-saporin as a model of dementia and its application - p. 849 128. Chapter 54. Amyloid beta 1–42-induced animal model of dementia: a review - p. 856 129. Chapter 55. Resources for the neuroscience of dementia - p. 856 130. Index of Volume 1 - p. 857 131. Index of Volume 2 - p. 897
